Course Description:
As part of USP’s response to the COVID-19 crisis, Remdesivir Methods containing analytical procedures (e.g., IR, UPLC, NMR, LC-MS) of identification and/or assay are in development. This course will cover the use of the methods, which can identify and reduce the risk of substandard and falsified Remdesivir and would support the digital/electronic standards model under evaluation.
The live version of this recording took place on June 22, 2021
Upon completion of this course, you will be able to:
- Analyze data developed in the Remdesivir Methods.
- Demonstrate analytical methods of ID and assay test for Remdesivir (e.g., IR, UPLC, LC-MS, qNMR—both high-field and benchtop platforms).
- Explicate each validation protocol of analytical methods and (digital) spectral information of Remdesivir.
Who should participate:
- Analytical scientists
- QA/QC analysts
- R&D scientists and managers
- Regulatory affairs specialists
- Contract research and manufacturing organizations staff
Before you attend this course it is suggested you take the free courses below:
- Determining Purity with Benchtop 1H NMR
- Interlaboratory Comparison of Benchtop NMR Spectrometers
- Development of a Reference-Free Quantification Method Using qNMR and Chromatography
- Drug Quality Control Applications for qNMR
- Pharmacopeial Applications of qNMR: A Selection of Vignettes
- qNMR in Complex Drug Product Quality: From Benchtop to High-Resolution
Access Duration:Access to this course expires 60 days from the date of registration or until you mark the course ‘Complete’ – whichever occurs first.
USP Approved Instructor
Mayank Bhanti, Ph.D.
USP Employee since 2019
Director, Compendial Development
Ph.D. in chemistry,